Related Experiment Video
Updated: Jun 22, 2025
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Advances in the Staging and Phenotyping of Cardiogenic Shock: Part 1 of 2
Jacob C Jentzer1, Corbin Rayfield2, Sabri Soussi3,4
1Department of Cardiovascular Medicine, Mayo Clinic Rochester, Rochester, Minnesota, USA.
Insights
Cardiogenic shock (CS) severity varies widely. New staging systems help predict outcomes and guide individualized treatment for CS patients, improving risk stratification and care.
Area of Science:
- Cardiology
- Critical Care Medicine
Background:
- Cardiogenic shock (CS) presents diverse clinical scenarios, impacting patient management and outcomes.
- Understanding CS heterogeneity is crucial for effective, individualized patient care.
Purpose of the Study:
- To review the context and established systems for clinical staging and stratification in cardiogenic shock.
- To explore the application of CS staging for risk stratification and predicting patient outcomes.
Main Methods:
- Review of current literature on cardiogenic shock severity staging.
- Analysis of validated algorithms for CS classification and risk stratification.
Main Results:
- Established severity staging systems for CS are available and validated.
- These staging systems aid in predicting outcomes and guiding clinical care for CS patients.
Conclusions:
- Clinical staging of cardiogenic shock is essential for tailored patient management.
- Severity staging and risk modifiers enable more nuanced, individualized care strategies for CS.
Abstract:
Cardiogenic shock (CS) is a heterogeneous syndrome reflecting a broad spectrum of shock severity, diverse etiologies, variable cardiac function, different hemodynamic trajectories, and concomitant organ dysfunction. These factors influence the clinical presentation, management, response to therapy, and outcomes of CS patients, necessitating a tailored approach to care. To better understand the variability inherent to CS populations, recent algorithms for staging the severity of CS have been described and validated. This paper is part 1 of a 2-part state-of-the-art review. In this first article, we consider the context for clinical staging and stratification in CS with a focus on established severity staging systems for CS and their use for risk stratification and clinical care. We describe the use of staging for predicting outcomes in populations with or at risk for CS, including risk modifiers that provide more nuanced risk stratification, and highlight how these approaches may allow individualized care.
